SCHEMBL4501570

SCHEMBL4501570

O=C(CN1CCN(CC(O)c2ccccc2)CC1)NC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
CHRM3 P20309 1/20 0.53
KDM4E B2RXH2 3/20 0.52
CYP3A4 P08684 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
RAB9A P51151 1/20 0.52
GAA P10253 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
DRD4 P21917 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50
BACE1 P56817 1/20 0.49
DRD3 P35462 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494539 0.99 ALDH1A1 (0.57) ALDH1A1CHRM3KDM4ECYP3A4HPGD
SCHEMBL27891189 0.80 KMT2A (0.58) ALDH1A1CHRM3KDM4EGAASIGMAR1
SCHEMBL1462492 0.79 MEN1 (0.59) CHRM3KDM4EGAAKMT2AMEN1
SCHEMBL6865166 0.78 SIGMAR1 (0.67) ALDH1A1GAASIGMAR1KMT2AMEN1
SCHEMBL11968938 0.78 KMT2A (0.56) ALDH1A1KDM4EGAAKMT2AMEN1
SCHEMBL3838578 0.77 KMT2A (0.70) ALDH1A1KDM4EGAAKMT2AMEN1
SCHEMBL24580906 0.76 SIGMAR1 (0.59) ALDH1A1CHRM3CYP3A4HPGDCYP2C19
SCHEMBL10746494 0.76 GAA (0.82) ALDH1A1KDM4EGAAKMT2AMEN1
SCHEMBL2796836 0.76 GAA (0.82) ALDH1A1KDM4EGAAKMT2AMEN1
SCHEMBL4501436 0.75 KDM4E (0.57) ALDH1A1KDM4ERAB9AGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US disclosed
US-7205303-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-04-17 US disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176356-A1 Substituted heterocyclic compounds KCNH1, KCNJ2, SCN5A ALDH1A1 215/4885CHRM3 1296/4885KDM4E 3425/4885
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A ALDH1A1 281/4885CHRM3 1532/4885KDM4E 2949/4885
US-20070155728-A1 Substituted Heterocyclic Compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885CHRM3 1532/4885KDM4E 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.